ScholarIQanswers from OpenAlex & ORCID
Eiichi Sato
ResearcherPublications, citations & collaboration network
Eiichi Sato is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Eiichi Sato have?
ScholarIQindexed works
Eiichi Sato has 399 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Eiichi Sato have?
ScholarIQcitation count
Eiichi Sato has 16,649 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Eiichi Sato?
ScholarIQh-index
Eiichi Sato has an h-index of 62 in OpenAlex.
What is the i10-index of Eiichi Sato?
ScholarIQi10-index
Eiichi Sato has an i10-index of 196 in OpenAlex.
What is the OpenAlex record for Eiichi Sato?
ScholarIQopenalex
The OpenAlex for Eiichi Sato is on the source record.
What are the most-cited papers on Eiichi Sato?
ScholarIQmost cited works
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Takuro Saito, Hiroyoshi Nishikawa, Hisashi Wada, Yuji Nagano, Daisuke Sugiyama, Koji Atarashi, Yuka Maeda, Masahide Hamaguchi, Naganari Ohkura, Eiichi Sato, Hirotsugu Nagase, Junichi Nishimura, Hirofumi Yamamoto, Shuji Takiguchi, Takeshi Tanoue, Wataru Suda, Hidetoshi Morita, Masahira Hattori, Kenya Honda, Masaki Mori, Yuichiro� Doki, Shimon Sakaguchi
Anti-CCR4 mAb selectively depletes effector-type FoxP3 <sup>+</sup> CD4 <sup>+</sup> regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama, Hiroyoshi Nishikawa, Yuka Maeda, Megumi Nishioka, Atsushi Tanemura, Ichiro Katayama, Sachiko Ezoe, Yuzuru Kanakura, Eiichi Sato, Yasuo Fukumori, Julia Karbach, Elke Jäger, Shimon Sakaguchi
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
Padmanee Sharma, Yu Shen, Sijin Wen, Sachiko Yamada, Achim A. Jungbluth, Sacha Gnjatic, Dean F. Bajorin, Victor E. Reuter, Harry W. Herr, Lloyd J. Old, Eiichi Sato
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk
Peter Willeit, Lena Tschiderer, Elias Allara, Kathrin Reuber, Lisa Seekircher, Lu Gao, Ximing Liao, Eva Lonn, Hertzel C. Gerstein, Salim Yusuf, Frank P. Brouwers, Folkert W. Asselbergs, Wiek H. van Gilst, Sigmund A. Anderssen, Diederick E. Grobbee, John J.P. Kastelein, Frank L.J. Visseren, George Ntaios, Apostolos Hatzitolios, Christos Savopoulos, Pythia T. Nieuwkerk, Erik Stroes, James Walters, Peter Higgins, Jesse Dawson, Paolo Gresele, Giuseppe Guglielmini, Rino Migliacci, М. В. Ежов, Maya Safarova, Т. В. Балахонова, Eiichi Sato, Mayuko Amaha, Tsukasa Nakamura, Kostas Kapellas, Lisa Jamieson, Michael R. Skilton, James A. Blumenthal, Alan L. Hinderliter, Andrew Sherwood, Patrick J. Smith, Michiel A. van Agtmael, Peter Reiss, Marit G. A. van Vonderen, Stefan Kiechl, Gerhard Klingenschmid, Matthias Sitzer, Coen D.A. Stehouwer, Heiko Uthoff, Zhi-Yong Zou, Ana Rosa Cunha, Mário Fritsch Neves, Miles D. Witham, Hyun Woong Park, Moo‐Sik Lee, Jang‐Ho Bae, Enrique Bernal, Kristian Wachtell, Sverre E. Kjeldsen, Michael Hecht Olsen, David Preiss, Naveed Sattar, Edith D. Beishuizen, Menno V. Huisman, Mark A. Espeland, Caroline Schmidt, Stefan Agewall, Ercan Ok, Gülay Aşçı, Eric de Groot, Muriël P.C. Grooteman, Peter J. Blankestijn, Michiel L. Bots, Michael Sweeting, Simon G. Thompson, Matthias Lorenz, For the PROG-IMT and the Proof-ATHERO Study Groups
Blockade of EGFR improves responsiveness to PD-1 blockade in <i>EGFR</i> -mutated non–small cell lung cancer
Eri Sugiyama, Yosuke Togashi, Yoshiko Takeuchi, Sayoko Shinya, Yasuko Tada, Keisuke Kataoka, Kenta Tane, Eiichi Sato, Genichiro Ishii, Kōichi Goto, Yasushi Shintani, Meinoshin Okumura, Masahiro Tsuboi, Hiroyoshi Nishikawa